Evaluating Trop2-ADC treatment for advanced triple-negative breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, randomized controlled study aims to assess the efficacy and safety of Trop2-ADC monotherapy and various combination therapies in patients with advanced triple-negative breast cancer. Participants will receive treatment with a Trop-2-targeting antibody-drug conjugate (ADC) either alone or in combination with immunotherapy and anti-angiogenic agents. The study will evaluate treatment efficacy over three months, focusing on overall response rates and monitoring for potential adverse events. Regular assessments will include imaging and histopathological analysis to ensure patient safety and treatment effectiveness.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\) adult female patients (aged 18-70 years) with metastatic triple negative breast cancer confirmed by pathology or imaging;
* 2\) no more than two previous lines of therapy for metastatic disease;
* 3\) ECOG performance status ≤2 and expected survival time ≥ 3 months;
* 4\) At least one measurable lesion on imaging within 2 weeks before enrollment; Or simple bone metastases;
* 5\) Prior treatment-related toxicity at enrollment had to be resolved to NCI CTCAE version 5.0 ≤ grade 1 (excluding alopecia or any other toxicity deemed by the investigator to be of no risk to patient safety)
* 6\) adequate bone marrow reserve: a. White blood cell count (WBC) ≥3.0×10\^9 / L, b. Neutrophil count (ANC) ≥1.5×10\^9 / L, c. Platelet count (PLT) ≥70×10\^9 / L
* 7\) liver, kidney and heart function tests were basically normal (according to the normal values of the laboratories in the study center) : a. Total bilirubin (TBIL) ≤3× upper limit of normal value (ULN), b. alanine aminotransferase and aspartate aminotransferase (ALT/AST) ≤2.5×ULN (≤5xULN in patients with liver metastases), c. Total bilirubin (TBIL) ≤3× upper limit of normal value (ULN), B. alanine aminotransferase and aspartate aminotransferase (Alt /AST) ≤2.5×ULN (≤5xULN in patients with liver metastases). Serum creatinine ≤1.5×ULN or creatinine clearance (Ccr) ≥60 ml/min; d. Left ventricular ejection fraction (LVEF) ≥ 55%, e. QTcF(Fridericia correction) ≤ 470 ms.
* 8\) understood the study process and volunteered to participate in the study. Informed consent was signed.

Exclusion Criteria:

* 1\) patients with a known allergy to the active ingredient or other ingredient of the study drug.
* 2\) patients with known resistance to trop2-ADC drugs. 、
* 3\) receiving radiotherapy, chemotherapy, or endocrine therapy within 4 weeks before enrollment, or participating in any interventional drug clinical trial;
* 4\) pregnant or lactating women or women of childbearing age who refused to use effective contraception during the study period.
* 5\) patients with severe cardiac disease or discomfort expected to be unable to tolerate chemotherapy, including but not limited to: fatal arrhythmia or higher grade atrioventricular block, unstable angina pectoris, clinically significant valvular heart disease, transmural myocardial infarction on ECG, uncontrolled hypertension;
* 6\) any other condition considered by the investigator to be inappropriate for participation in the study, a concomitant disease or condition that could interfere with participation in the study, or any serious medical disorder that could affect the safety of the subject (e.g., uncontrolled heart disease, hypertension, active or uncontrolled infection, active hepatitis B virus infection)；

Where it's running

• Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China;
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Zhao JL Professor
• Email: zhaojianli1988@126.com
• Phone: +86 15920589334

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BEBT-209 plus chemotherapy in advanced/metastatic triple-negative breast cancer

  A new drug, BEBT-209, is being tested with standard chemotherapy to see if it helps people with locally advanced or metastatic triple-negative breast cancer.

  Recruiting at 2 sites Phase 2/3 BeBetter Med Inc · Guangzhou, Guangdong and 1 other locations · NCT07544056

• TASTY taste-steering for chemotherapy-related taste changes

  This trial tests whether an at-home 'taste steering' program helps adults on chemotherapy for metastatic triple-negative breast cancer, metastatic testicular cancer, or stage II–IV diffuse large B cell lymphoma enjoy food more.

  Recruiting at 6 sites University Medical Center Groningen · Amsterdam and 10 other locations · NCT07258563

• Naxitamab plus sacituzumab govitecan for metastatic triple-negative breast cancer

  This trial will test whether combining naxitamab with sacituzumab govitecan helps adults with metastatic triple-negative breast cancer.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT07011654

• Sacituzumab govitecan with nivolumab, with or without relatlimab, for metastatic triple-negative breast cancer

  This trial tests whether adding nivolumab alone or nivolumab plus relatlimab to sacituzumab govitecan helps people with metastatic triple-negative breast cancer who have had one prior line of chemotherapy.

  Recruiting Phase 1/2 Yale University · New Haven, Connecticut · NCT06963905

• Combining SDX-7320 with Eribulin for Treating Breast Cancer

  This study is testing if adding the drug SDX-7320 to the standard chemotherapy eribulin can help people with metastatic triple-negative breast cancer and metabolic issues feel better.

  Recruiting at 10 sites Phase 2 Memorial Sloan Kettering Cancer Center · Miami, Florida and 9 other locations · NCT05570253

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.